Our final look at third-quarter events focuses this time on the smallest players, with data from Amryt, Ovid, Bellus and more.
Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.
Biogen’s aducanumab filing is keenly awaited, as are clinical data from Sanofi, Bristol Myers Squibb, Lilly and others.
Last month the FDA greenlit four oncology approvals early and the first GnRH antagonist in uterine fibroids.
Astrazeneca’s Lynparza is due US approval decisions in prostate and ovarian cancers, while Bristol's Opdivo’s fate will be determined in lung cancer.
Coronavirus aside, biotech companies including Akebia, Blueprint, Genfit and TG Therapeutics are set for some important data readouts in the next couple of months.
A Vantage analysis of FDA decisions expected in the next month and how the ongoing Covid-19 pandemic could affect these.
Several key data readouts slated for the first quarter remain unannounced, from Roche, Lilly, Axsome and others, but the Covid-19 pandemic puts many at risk of delay.
Phase III data for Obseva's uterine fibroid project linzagolix need to prove its safety, while Inventiva tests its pan-PPAR agonist lanifibranor in Nash.